Uncategorized – Bio Code

IGF-1 LR3 1mg

OneDraft Studio LLC — Mon, 13 Oct 2025 18:47:51 +0000

IGF-1 LR3 – 1 mg

(Insulin-Like Growth Factor-1 Long Arg3 Analog)

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a recombinant analog of human IGF-1, modified to extend its half-life and enhance biological activity in experimental settings. It differs from native IGF-1 by the substitution of arginine for glutamic acid at position 3 and an additional 13-amino-acid extension at the N-terminus, which significantly reduces its binding affinity to IGF-binding proteins (IGFBPs).

These modifications allow IGF-1 LR3 to remain active longer and interact more freely with cellular IGF-1 receptors, promoting sustained anabolic and regenerative signaling in research models investigating growth, repair, and metabolic pathways.

Mechanism of Action (Based on Preclinical and Clinical Research):

IGF-1 receptor activation: Binds to IGF-1R, initiating PI3K/Akt and MAPK pathways that regulate cell growth, repair, and survival.
Reduced IGFBP affinity: Decreased binding to IGFBPs extends duration of activity and enhances receptor availability.
Anabolic stimulation: Promotes protein synthesis, muscle cell differentiation, and satellite cell activation.
Cellular regeneration: Supports tissue recovery through proliferation of fibroblasts, myocytes, and neuronal cells.
Insulin-mimetic action: Influences glucose uptake and nutrient utilization in research models.

Potential Benefits (Based on Preclinical Research):

Enhanced muscle and tissue growth in experimental studies
Promotion of cellular repair and regeneration
Improved protein synthesis and nutrient transport
Support for neuroprotective and metabolic research
Extended biological activity compared to native IGF-1
Applications in anabolic, regenerative, and longevity-based investigations

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

GHRP-2 10mg

OneDraft Studio LLC — Mon, 13 Oct 2025 18:33:25 +0000

GHRP-2 – 10 mg

(Growth Hormone Releasing Peptide-2)

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide belonging to the ghrelin mimetic family, designed to stimulate the release of endogenous growth hormone (GH) through activation of the ghrelin receptor (GHS-R1a). It functions independently of the hypothalamic GHRH pathway, providing a direct and potent stimulus to the pituitary gland to promote pulsatile GH secretion in research models.

Extensively studied in both animal and early human research, GHRP-2 has been evaluated for its potential roles in metabolism, muscle growth, cellular regeneration, and immune modulation.

Mechanism of Action (Based on Preclinical and Clinical Research):

Ghrelin receptor activation: Binds to and activates GHS-R1a, mimicking the natural ligand ghrelin to stimulate GH release.
Pituitary stimulation: Induces growth hormone secretion through both hypothalamic and pituitary pathways.
Synergistic interaction: Demonstrates additive effects when combined with GHRH analogs such as CJC-1295.
Metabolic regulation: Enhances protein synthesis, supports lipid metabolism, and may increase appetite in experimental models.
Neuroendocrine influence: Modulates stress, energy balance, and sleep patterns in research settings.

Potential Benefits (Based on Preclinical Research):

Increased pulsatile growth hormone and IGF-1 levels
Enhanced muscle recovery and protein synthesis
Improved lipid utilization and body-composition regulation
Investigated for anti-aging and regenerative-biology models
Synergistic applications with other GH secretagogues (e.g., CJC-1295, GHRP-6)

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

KLOW

OneDraft Studio LLC — Mon, 13 Oct 2025 18:28:47 +0000

KLOW – 80 mg

(Advanced Regenerative Peptide Complex: BPC-157, TB-500, GHK-Cu, KPV)

KLOW is a multi-component peptide formulation designed to explore synergistic mechanisms of cellular repair, inflammation control, and tissue regeneration in research models. Combining four distinct bioactive peptides — BPC-157, TB-500, GHK-Cu, and KPV — KLOW targets multiple biological pathways involved in recovery, angiogenesis, and anti-inflammatory signaling.

Each component contributes a unique role: BPC-157 and TB-500 promote tissue regeneration and cellular migration; GHK-Cu supports collagen synthesis and skin repair through copper-mediated enzymatic activity; and KPV, a tripeptide derived from α-MSH, provides potent anti-inflammatory and antimicrobial modulation. Together, they form a comprehensive model for studying regenerative and recovery-oriented biological responses.

Mechanism of Action (Based on Preclinical and Clinical Research):

BPC-157: Enhances angiogenesis, fibroblast migration, and connective-tissue healing through modulation of nitric oxide and growth-factor pathways.
TB-500 (Thymosin Beta-4 fragment): Promotes actin regulation, cell migration, and vascular growth, supporting accelerated wound and muscle recovery.
GHK-Cu: Stimulates collagen synthesis, cellular remodeling, and wound repair via copper ion-mediated enzymatic signaling.
KPV: Exhibits anti-inflammatory and immunomodulatory properties by inhibiting NF-κB and cytokine activity, supporting epithelial integrity and healing.
Synergistic action: Combines tissue repair, angiogenesis, and inflammation control within a unified regenerative framework.

Potential Benefits (Based on Preclinical Research):

Accelerated wound and tissue healing
Enhanced muscle, tendon, and ligament recovery
Support for skin regeneration and collagen remodeling
Reduction of localized and systemic inflammation
Potential antimicrobial and cytoprotective effects
Investigated for applications in regenerative medicine, tissue engineering, and anti-inflammatory research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

DSIP 5mg

OneDraft Studio LLC — Mon, 13 Oct 2025 18:24:31 +0000

DSIP – 5 mg

(Delta Sleep-Inducing Peptide)

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide first identified in the hypothalamus and characterized by its potential to modulate sleep patterns, stress response, and neuroendocrine regulation. The synthetic form of DSIP has been studied in experimental models for its influence on the central nervous system, its adaptogenic properties, and its potential role in maintaining homeostasis under physiological stress.

Research has explored DSIP for its neuroprotective, antioxidant, and sleep-modulating effects, as well as for its potential to support pituitary hormone balance and cellular recovery mechanisms.

Mechanism of Action (Based on Preclinical and Clinical Research):

Neuroendocrine modulation: Interacts with hypothalamic and pituitary pathways influencing hormonal balance, particularly ACTH, LH, and GH secretion.
Sleep regulation: Promotes natural sleep cycles and normalization of circadian rhythms in experimental subjects.
Neuroprotective effects: Demonstrates antioxidant and anti-stress activity within central nervous system models.
Mitochondrial support: May stabilize cellular energy processes and protect against oxidative stress.
Corticosteroid modulation: Studied for reducing stress-induced elevations in cortisol levels.

Potential Benefits (Based on Preclinical Research):

Normalization of sleep architecture and circadian rhythm
Reduction of stress-related responses in neurological models
Potential enhancement of recovery and cellular resilience
Support for neuroprotection and hormonal balance
Investigated for applications in fatigue, adaptation, and stress physiology research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

CJC-1295 with DAC 5 mg

OneDraft Studio LLC — Mon, 13 Oct 2025 18:20:45 +0000

CJC-1295 with DAC – 5 mg

(Growth Hormone Releasing Hormone Analog with Drug Affinity Complex)

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH 1-29) engineered to extend the half-life and duration of GHRH activity through covalent binding to plasma proteins. This modification allows for prolonged and stable stimulation of endogenous growth-hormone release in research models, distinguishing it from shorter-acting GHRH analogs.

The compound has been widely studied in preclinical and early-phase clinical research for its potential to enhance pulsatile growth-hormone secretion, support cellular regeneration, and improve metabolic and recovery-related parameters.

Mechanism of Action (Based on Preclinical and Clinical Research):

GHRH receptor activation: Stimulates the anterior pituitary to release endogenous growth hormone (GH).
DAC modification: The Drug Affinity Complex binds to albumin, extending peptide half-life and allowing for sustained GH release.
Pulsatile GH secretion: Mimics natural growth-hormone rhythms, supporting downstream IGF-1 production.
Cellular and tissue support: Promotes protein synthesis, cellular repair, and lipid metabolism via GH/IGF-1 pathways.
Improved bioavailability: Reduces frequency of administration compared to non-DAC GHRH analogs.

Potential Benefits (Based on Preclinical Research):

Sustained increase in GH and IGF-1 levels in experimental models
Improved muscle recovery and tissue regeneration
Enhanced lipid metabolism and body-composition modulation
Investigated for potential anti-aging and cellular-repair effects
Studied for synergy with GHRPs and other GH-secretagogues

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

BPC-157 5mg

OneDraft Studio LLC — Mon, 13 Oct 2025 18:18:11 +0000

BPC-157 – 5 mg

(Body Protection Compound-157)

BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a naturally occurring protective protein found in the gastric juices of the human body. It has been extensively studied in preclinical models for its potential role in promoting tissue repair, angiogenesis, and cellular regeneration.

Research suggests that BPC-157 supports the healing of tendons, ligaments, muscles, and the gastrointestinal tract by enhancing growth factor expression and modulating inflammatory pathways. Its broad biological activity has made it a key focus in experimental models studying recovery, injury repair, and inflammatory regulation.

Mechanism of Action (Based on Preclinical and Clinical Research):

Angiogenic effects: Promotes the formation of new blood vessels through upregulation of VEGF and related growth factors.
Cytoprotective properties: Protects cells under oxidative and inflammatory stress conditions.
Collagen synthesis stimulation: Enhances fibroblast activity and collagen production to support connective tissue repair.
Neuromodulatory activity: Demonstrates protective effects on the central and peripheral nervous systems in injury models.
Gastrointestinal healing: Interacts with nitric oxide pathways to accelerate mucosal and intestinal regeneration.

Potential Benefits (Based on Preclinical Research):

Accelerated tendon, ligament, and muscle recovery
Enhanced wound healing and angiogenesis
Reduced inflammation and oxidative damage
Protection of gastrointestinal lining and tissues
Studied for potential neuroprotective and joint-repair properties
Applications in research focused on regenerative and recovery-based biology

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.